Eric Halioua

📢 PDC*lung01 Phase I/II results now published in ESMO Open! authors.elsevier.com/sd/article/S20… Publication of the Phase I/II clinical study evaluating the therapeutic cancer vaccine PDC*lung01 in patients with non-small cell lung cancer in ESMO Open – the journal of the @myESMO

-> Don’t miss this article!

In this interview, Eric Halioua reflects on the start, success and momentum of PDC*line Pharma, a clinical-stage biotechnology company developing allogeneic cellular immunotherapies for cancer. He also shares three top tips for start-up companies on their investment and funding journey and highlights the importance of connecting through conferences. Read now >>> hubs.ly/Q03mwxvQ0

📢 @pdc_line at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. 📷 Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1

Excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025 next week in Bruges, Belgium! This year’s theme — “Can European biotech rise to the complexity of the moment?” — couldn’t be more timely. 📅 Learn more: lnkd.in/ebxFNqDm

👉 New Video following poster presentation at the European Lung Cancer Congress 2025 #ELCC2025 21P PDC*lung01 cancer vaccine. We are pleased to share a video presentation by Prof. Dr. Johan Vansteenkiste, the principal investigator of our clinical trial medimix.be/onco/?p=16201

Highlights from ELCC Day 3 @alessandra_dodi @Alfdoc2 @SuyogCancer @Tony_Calles @HaliouaEric @g_mountzios @NReguart @Dr_Ivanoncologo @DrJNaidoo @MOcchipintiMD oncodaily.com/societies/2633… #Cancer #ELCC #ELCC2025 #ELCC25 #ESMO #MedX #MedEd #LungCancer #NSCLC #OncoDaily #Oncology #ThoracicOncology #Medicine #Health #MedOnc

🤝 Clap de fin pour le Festival #Imagésanté ! Toute l’équipe de @pdc_line Pharma est ravie d’avoir une nouvelle fois soutenu cette belle initiative! 📺 Si vous avez manqué cette table ronde, vous pouvez la (re)voir ici 👉 lnkd.in/ek7GCbBe

PDC*line Pharma Unveils New Clinical Results with PDC*lung01 at the #ELCC2025 . Poster Title: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDClung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study

Exciting news! Our abstract has been accepted for a poster presentation at #ELCC2025. We’re proud to share new data from our ongoing clinical development program with PDC*lung01, our therapeutic cancer vaccine NSCLC. lnkd.in/eMeKgmBn

Tomorrow’s the day! I’m excited to be speaking at Advanced Therapies UK 2025, where industry leaders will meet for two days of insightful discussions, networking, and innovation. There’s still time to join us in London—don’t miss out. #adtherapies i.snoball.it/p/GWhk/t/5

I’m thrilled to be attending the J.P. Morgan Conference in San Francisco from Sunday to Wednesday evening. If you’re attending as well and would like to connect, feel free to reach out or meet me at the conference. Looking forward to dynamic discussions in this hub of innovation!

I’m thrilled to be hosting an Executive Roundtable at @WuXi_AppTec #WuXiGlobalForum during #JPM2025! I’m excited to discuss about opportunities of innovative cancer vaccines ! Learn more about the event here: lnkd.in/e36tbuAt

We are thrilled to share the primary clinical results from our Phase I/II trial of the PDC*lung01 cancer vaccine, presented at ESMO-IO 2024! PDC*lung01, combined with pembro, shows potential for meaningful clinical benefit compared to pembro alone in stage IV NSCLC patients.

New Article Featuring CEO of @pdc_line Published in @BioprocessIC Interview provides valuable insights into the driving force behind our innovative platform, the resilience required to thrive in the industry, and the transformative role of global partnerships in our success.

New Article Featuring Our CEO @HaliouaEric Published in @BioprocessIC Eric provides valuable insights into the driving force behind our innovative platform, the resilience required to thrive in the industry, and the transformative role of global partnerships in our success.

@pdc_line announces that the primary clinical results from its PDC-LUNG-101 trial will be presented as a mini oral presentation at the @myESMO - IO Congress! The congress will be held in Geneva, from December 11-13, 2024. Prof. Johan F. Vansteenkiste will present these results.

We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the SFHI, held in Strasbourg from October 9 to 11, 2024!🔗 Learn more about the event: ttps://lnkd.in/gz5SQndR